MDVN 111.22 Medivation Inc $MDVN Hit a 52 week high of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 12:11 PM

MDVN 111.22 Medivation Inc $MDVN Hit a 52 week high of 113.48 Currently at 111.22 -1.55 -1.37% With a day low of 111.37 and a total volume of 72,503.

MDVN Medivation Inc Recent Headline News

Uptrend Call Working As Medivation Stock Rises 15.2% (MDVN)
Comtex SmarTrend(R) - 1 hr 32 mins ago
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on October 21st, 2014 at $96.87. In approximately 3 weeks, Medivation has returned 15.20% as of today's recent price of $111.60.
MDVN: 110.35 (-2.42)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - 2 hrs 47 mins ago
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 110.35 (-2.42), ABMD: 32.58 (+0.45), JNJ: 108.48 (+0.28), AMGN: 162.54 (+2.29), EXAS: 22.59 (-0.23), ARAY: 6.85 (unch), HOLX: 26.45 (+0.24), PBYI: 240.65 (+3.76)

The Next Chapter in Dendron's Troubled History: Chapter 11 Bankruptcy
at The Street - Mon Nov 10, 6:12AM CST
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
MDVN: 110.35 (-2.42), JNJ: 108.48 (+0.28), DNDN: 0.23 (-0.71)

5 Prescription Drugs Selling Like Hot Cakes
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 09, 9:01AM CST
Considering that 90% of prescription drugs being developed by biotechnology companies will fail during clinical trials, it can be tough to know which biotech stocks to seize upon and which stocks to shun. Instead of focusing on unproven...
MDVN: 110.35 (-2.42), JNJ: 108.48 (+0.28), BIIB: 324.99 (+4.24), PTLA: 27.25 (-0.14), GILD: 108.25 (+1.80), CELG: 107.80 (+1.35)

Look for Shares of Medivation to Potentially Pullback after Yesterday's 7.45% Rise
Comtex SmarTrend(R) - Fri Nov 07, 3:46PM CST
Medivation (NASDAQ:MDVN) traded in a range yesterday that spanned from a low of $102.04 to a high of $113.61. Yesterday, the shares gained 7.5%, which took the trading range above the 3-day high of $106.79 on volume of 3.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MDVN: 110.35 (-2.42)

Clarification: Earns-Medivation story
AP - Fri Nov 07, 11:53AM CST
SAN FRANCISCO (AP) — In a story Nov. 7, The Associated Press reported that Medivation Inc. missed third-quarter earnings and revenue expectations based on the average of seven forecasts from Zacks Investment Research. The story was later updated to reflect that the company beat expectations based on the average of 18 estimates from FactSet.
MDVN: 110.35 (-2.42)

Medivation Q3 Earnings, Revenues Lag Estimates - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri Nov 07, 11:08AM CST
Medivation's (MDVN) Xtandi should see strong uptake in the chemo-naive patient population from the fourth quarter.
CYTK: 4.17 (+0.07), MDVN: 110.35 (-2.42), BIIB: 324.99 (+4.24)

Medivation Hits High After Q3 Earnings Beat
at Investor's Business Daily - Fri Nov 07, 10:15AM CST
Biotech Medivation (MDVN) jumped to a new high in the stock market today after its Q3 results beat estimates late Thursday on strong sales of cancer drug Xtandi. Medivation's earnings totaled 96 cents a share, reversing a year-earlier loss and...
MDVN: 110.35 (-2.42), AOL: 44.22 (+1.54), AZN: 73.26 (+0.38)

Medivation Reports Third Quarter Financial Results and Provides Corporate Update
Marketwired - Thu Nov 06, 3:13PM CST
Medivation, Inc. (NASDAQ: MDVN) today reported its financial results for the third quarter ended September 30, 2014. U.S. net sales of XTANDI(R) (enzalutamide) capsules for the quarter, as reported by Astellas Pharma Inc., were $181.4 million (+67% vs. prior year). Ex-U.S. net sales of XTANDI for the quarter, as reported by Astellas, were $119.6 million.
MDVN: 110.35 (-2.42)

Medivation Announces Participation at Upcoming Investor Conference
Marketwired - Wed Nov 05, 3:11PM CST
Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:
MDVN: 110.26 (-2.51)

3 Biotech Stocks for Earnings Beats this Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 12:38PM CST
Many biotech stocks are exploring their own ways to emerge as winners.
MDVN: 110.26 (-2.51), ENDP: 69.36 (+0.40), AUXL: 32.91 (+0.16), SHPG: 201.46 (+2.88), DNDN: 0.23 (-0.71), SNSS: 1.60 (-0.03), ABBV: 63.79 (+2.29), SNY: 46.32 (+0.63), MNKD: 5.81 (+0.03), XOMA: 3.84 (+0.03)

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline
at The Street - Wed Nov 05, 7:00AM CST
The diversification away from Xtandi has only just begun.
MDVN: 110.26 (-2.51)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 110.31 (-2.46), ACT: 247.52 (+1.61), PRGO: 156.39 (+0.62), ALNY: 98.53 (+2.69)

Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.65 (-0.05), MDVN: 110.31 (-2.46), ALNY: 98.38 (+2.54), HUM: 132.82 (+2.24)

Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.17 (+0.07), MDVN: 110.31 (-2.46), BIIB: 324.99 (+4.24), GERN: 2.25 (-0.08)

Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 110.31 (-2.46), ONCY: 0.81 (+0.11), GERN: 2.25 (-0.08), ILMN: 189.47 (+3.12)

Is Hospira (HSP) Poised to Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 4:00PM CST
Hospira (HSP), which is scheduled to report third-quarter 2014 results on Nov 6, had posted a positive earnings surprise of 28.57%.
MDVN: 110.31 (-2.46), ACT: 247.52 (+1.61), ALNY: 98.38 (+2.54), HSP: 56.29 (-0.03)

Will DaVita Healthcare (DVA) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 1:40PM CST
DaVita Healthcare Partners, Inc. (DVA) is set to report third-quarter 2014 earnings on Nov 6, 2014.
MDVN: 110.31 (-2.46), AMSG: 51.29 (-0.21), DVA: 74.51 (+0.02), ALNY: 98.38 (+2.54)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Reimagining Water: A Crisis and a Call to Action

Time for a Change The head of the World Water Council, Loïc Fauchon, didn't mince words at the 9th Cairo Water Week. He proclaimed the old methods of water management are sinking under a flood of modern challenges. Toss in climate upheavals, ballooning cities, and unpredictable diets, and you've got yourself a swirling mess that traditional strategies just can’t mop...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

ROKAE Hits 10,000 Delivery Mark for Robotic Arms

ROKAE's Big 10K: A Milestone Worth Noting Alright, if you've been around the block as long as I have, you know the robotics game isn't just about making cool gadgets—it's about hitting those serious deployment numbers. ROKAE Robotics just rolled its 10,000th humanoid force-controlled arm off the line in Shandong, and this ain't just another notch on their belt. This...

Redwood and SAP Partner on Secure File Transfer

Redwood Advances SAP Interiors with New File Solution October 26, '26 is now a landmark for Redwood Software. They've just rolled out their SAP Managed File Transfer solution. Got the brainpower behind Redwood and SAP operating together here, and they're offering this to enterprises aimed at optimizing their file-based workflow. If you're scratching your head just hearing...

Love Business Group Helps SMEs Navigate Broadband Choices

Understanding Broadband Needs for UK SMEs When you're knee-deep in running a small biz in the UK, sorting out your broadband needs can feel like sifting through a thousand-piece puzzle. Enter Love Business Group, getting a nod of recognition for being the SME knight in shining armor. Aimed at businesses of all sizes, they've been pegged by Expert Consumers for helping...

Ericsson Executes Bold Share Buyback Plan in Oct.

Ericsson Kicks Off October with Major Share Repurchases Ericsson's taking bold steps in consolidating shareholder value, and folks, this ain't your run-of-the-mill stock-in-the-drawer move. Between October 19 and 23, 2026, Ericsson picked up 500,000 of its own Class B shares. Yep, you heard right—half a million shares just like that, with a neat price tag rounding out...

SWI Compute's Bold Move: Transforming Power Into AI

The Power Play: From Grid to AI If you think turning megawatts into money-making machines is a stretch, think again. SWI Compute is daringly striding into this territory with the launch of its NVIDIA AI factories in Europe, backed by a hefty 3.6 gigawatts of secured power capacity. It's not just talk; they've got the juice, both in electricity and ambition, to boot....

Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...